logo-loader
viewHeat Biologics

Heat Biologics reveals positive patient survival data from its Phase 2 lung cancer trial

Heat Biologics, Inc (NASDAQ:HTBX) Chief Scientific and Operating Officer Jeff Hutchins tells Proactive the North Carolina-based biotech presented positive patient survival data from its Phase 2 lung cancer trial at the American Society of Clinical Oncology annual meeting.

Hutchins says Heat's therapy HS-110 in combination with Bristol-Myers Squibb's nivolumab showed significantly greater median overall survival of 42.1 months compared to a median overall survival of 28.7 months in previously treated patients.

Quick facts: Heat Biologics

Price: 0.9357 USD

NASDAQ:HTBX
Market: NASDAQ
Market Cap: $79.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Heat Biologics named herein, including the promotion by the Company of Heat Biologics in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Heat Biologics doses first patient in its Phase 1 clinical trial evaluating...

Heat Biologics, Inc subsidiary Pelican Therapeutics CEO Rahul Jasuja tells Proactive the clinical-stage biopharmaceutical company has dosed its first patient in its first-in-human Phase 1 clinical trial evaluating PTX-35 as an anti-cancer drug. Jasuja says this first-in-human study is...

2 weeks, 4 days ago

2 min read